Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

Research and development expenses rose by 1.6% to euro 1,108 million. At constant exchange rates, they were down by 2.5%, reflecting selectivity in R&D projects and cost savings.

Selling and general expenses increased by 5.9%, or 1.5% at constant exchange rates, to euro 1,895 million. The ratio of selling and general expenses to net sales fell by 1.2 points to 25.5%, reflecting the ongoing program of adaptation to market conditions.

Other current operating income, net of expenses totaled euro 132 million, compared with euro 74 million for the second quarter of 2008. The year-on-year change in this line reflects gains on currency hedging and an increase in the royalty collected by sanofi-aventis on sales of Copaxone((R)) in North America.

Operating income - current was up 26.8% at euro 3,046 million. At constant exchange rates, growth was 16.0%. The ratio of operating income - current to net sales improved by 5.1 points to 41.0%.

Net financial expenses were virtually unchanged at euro 70 million. Financial expenses rose slightly, reflecting the change in net debt arising from payment of the Zentiva purchase consideration at the end of the first quarter and from the dividend payout.

The effective tax rate was 0.6 of a point lower at 29%, in line with the 2008 full-year rate.

The share of profits from associates was up 22.6% at euro 266 million, with the share of after-tax profits from territories managed by BMS under the Plavix((R)) and Avapro((R)) alliance 42.7% higher at euro 207 million due to a good performance by Plavix((R)) in the United States and a favorable dollar effect. The contribution from Merial rose by 21.6%, and the contribution from Sanofi Pasteur MSD also grew.

Minority interests were 5.7% higher at euro 111 million. The share of pre-tax profits paid to BM
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Israel Biomedical Sensors market is estimated at $0.19 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage Pharmaceuticals ... to an Investigational New Drug (IND) application for the ... recently completed a study in a rat model of ... significant efficacy and a more rapid onset of action ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015  MicuRx ... antibiotics, today announced positive top-line results from the ... drug candidate MRX-I. MRX-I is an oral oxazolidinone ... MRSA and VRE, while offering physicians and patients ... currently available oxazolidinone agents. "These ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare ... agreement to acquire YouMedical Group BV ("YouMedical"), a Dutch ... has total annual sales of approximately EUR 16 million, ... "Our ambition is to build a ... important step toward that goal. YouMedical gives us a ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... - Engineers at Rensselaer Polytechnic Institute have developed tools to ... of stem cell research how to quickly test stem ... create a large supply of healthy, viable stem cells to ... have created methods to study millions of stems cells on ...
... to discover life on Mars were successfully launched into ... experiment to assess their survivability in the space radiation ... approach is based on technology similar to that used ... in the Life Marker Chip (LMC) experiment, which has ...
... engineers often deal with the same problems, but they ... other can be difficult, if not impossible., A new ... by the National Science Foundation (NSF), will help bridge ... to solve common problems a range of scientists face., ...
Cached Biology Technology:Putting stem cell research on the fast track 2Putting stem cell research on the fast track 3Putting stem cell research on the fast track 4Life on Mars 'pregnancy test' successfully launched 2CCMR gets $2.9M for training grad students in nanoscale science 2
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... problem, there is a greater risk that you will consume ... Sahlgrenska Academy, at the University of Gothenburg, Sweden. ,It ... likely to have a drink problem in the future, and ... on this link. Carried out by researcher Anna Sderpalm Gordh, ...
... of Energy,s (DOE) Brookhaven National Laboratory and collaborators at the ... where to insert a double bond when desaturating plant fatty ... amino acid far from the enzyme,s active site solves ... control. The work, published in the Proceedings of the ...
... SuviCa Inc. of Boulder and the University of Colorado ... drug screening technology to identify novel therapies for cancer. ... CU-Boulder Associate Professor Tin Tin Su of the molecular, ... Drosophila fruit fly model to screen for compounds effective ...
Cached Biology News:Scientists solve long-standing plant biochemistry mystery 2Scientists solve long-standing plant biochemistry mystery 3Scientists solve long-standing plant biochemistry mystery 4SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology 2
... an excellent choice for supporting hydrocarbon processing. In ... this one-channel workhorse can double sample throughput by ... You get all the capability and reliability you ... that has the same proven performance of Agilents ...
... animal infusion kits reduce the time and ... while providing sterile equipment to reduce the ... you need for one animal, including swivel, ... will be cut to the exact lengths ...
... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...
... Gene silencing experiments often call for ... NeoFX Transfection Agent refines siRNA transfection ... NeoFXs lipid-based formulation can be used ... they are subcultured without increased ...
Biology Products: